Oncology Practice Management Issues


September 2016, Vol 6, No 9

FDA News – September 2016

FDA News

In This Article First Extended-Release Serotonin Receptor Antagonist Approved for the Prevention of CINV Keytruda Receives New Indication for Head and Neck Squamous-Cell Carcinoma Cabometyx Approved for Patients with Advanced Renal-Cell Carcinoma First Extended-Release Serotonin Receptor Antagonist Approved for the [ Read More ]